Lantheus Holdings Inc (LNTH) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Total Assets Chart for Lantheus Holdings Inc
Lantheus Holdings Inc (LNTH) total assets for FY2025 were USD 2.2B, a 12.5% change from FY2024. Lantheus Holdings Inc's total assets grew from USD 324.7M in 2012 to USD 2.2B in 2025 (586.1% over 13 years). Total assets compound annual growth rate: 5-year CAGR of 20.7%, 10-year CAGR of 24.8%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $6.53B
- Implied Share Price
- $99.95
- Enterprise Value
- $6.56B
- Revenue (TTM)
- $1.56B
- EBITDA
- $392.22M
- Profit Margin
- 17.69%
- Trailing P/E
- 24.20
- Forward P/E
- 14.27
- Price/Book (MRQ)
- 4.98
- Price/Sales (TTM)
- 4.19
- EV/EBITDA
- 13.92
- EV/Revenue
- 4.22
- Dividend Yield
- —
- Book Value
- $20.10
- Free Cash Flow (FY2025)
- $354.05M
- Free Cash Flow Yield
- 5.42%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.